Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China.

ABSTRACT: Compared to chemotherapy, promising results have been obtained by blocking the PD-1 pathway using antibodies that inhibit programmed cell death protein 1 (PD-1) or programmed cell death protein ligand 1 (PD-L1). Furthermore, global researchers and doctors are exploring how to optimize this immunotherapy in 270 clinical studies. However, Chinese clinical trials of these agents remain in the early stages. We summarize the ongoing international and domestic clinical trials using PD-1 and PD-L1 inhibitors to treat lung cancer. This information can help researchers better understand the active and approved clinical trials in China, as well as the ongoing research regarding PD-1 and PD-L1 inhibitors.

SUBMITTER: Liu SY 

PROVIDER: S-EPMC5499002 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature